BioVendor Group expands its IVDR-certified portfolio with a new CLIA kit for the detection of Chromogranin A (CgA), a universal biomarker for neuroendocrine tumors. CgA is secreted by all neuroendocrine cells, and its plasma levels correlate with tumor presence and progression. The new kit enables accurate and reliable quantification of CgA in human serum or plasma on the fully automated KleeYa® analyzer.
High diagnostic sensitivity and specificity are ensured through the use of recombinant or highly purified native antibodies. The assay is intended for both diagnosis a broad spectrum of neuroendocrine tumors, including carcinoids, pheochromocytomas, and small cell lung carcinomas.
Learn more about the CLIA Chromogranin A kit, including performance data and ordering information, on the product page:
